Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Phyo Than HtooHelen TesfayeSebastian G SchneeweissDeborah J WexlerBrendan M EverettRobert J GlynnNiklas SchmedtLisette KoenemanAnouk Déruaz-LuyetJulie M PaikElisabetta PatornoPublished in: Diabetologia (2024)
Empagliflozin relative to DPP-4i was associated with risk reductions of MI or stroke, HHF, MACE and the composite of cardiovascular mortality or HHF. Absolute risk reductions were larger in older individuals and in those who had history of ASCVD or heart failure. Regarding the safety outcomes, empagliflozin was associated with an increased risk of DKA and lower risks of AKI, hypoglycaemia and progression to proliferative retinopathy, with no difference in the short-term risks of lower-extremity amputation, non-vertebral fractures, kidney and renal pelvis cancer, and bladder cancer.
Keyphrases
- heart failure
- atrial fibrillation
- human health
- type diabetes
- acute kidney injury
- papillary thyroid
- physical activity
- risk assessment
- risk factors
- bone mineral density
- metabolic syndrome
- squamous cell
- young adults
- middle aged
- brain injury
- weight loss
- cardiac resynchronization therapy
- subarachnoid hemorrhage
- breast cancer risk